NASDAQ:ERAS

Erasca (ERAS) Stock Forecast, Price & News

$2.02

-0.15 (-6.91%)

(As of 09/28/2023 ET)

Compare

Today's Range: $1.98
▼
$2.20
50-Day Range: $2.12
▼
$2.91
52-Week Range: $1.98
▼
$9.25

Volume: 501,625 shs
Average Volume: 788,952 shs
Market Capitalization: $305.10 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $11.00

Erasca MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 444.6% Upside
$11.00 Price Target
Short Interest: Bearish
9.10% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.99
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.03) to ($1.26) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.18 out of 5 stars

Medical Sector

450th out of 969 stocks

Pharmaceutical Preparations Industry

200th out of 455 stocks

3.5

Analyst's Opinion

Consensus Rating
Erasca has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $11.00, Erasca has a forecasted upside of 444.6% from its current price of $2.02.
Amount of Analyst Coverage
Erasca has received no research coverage in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
9.10% of the float of Erasca has been sold short.
Short Interest Ratio / Days to Cover
Erasca has a short interest ratio ("days to cover") of 16.6, which indicates bearish sentiment.
Change versus previous month
Short interest in Erasca has recently decreased by 5.49%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Erasca does not currently pay a dividend.
Dividend Growth
Erasca does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ERAS.

3.3

News and Social Media Coverage

News Sentiment
Erasca has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Erasca this week, compared to 1 article on an average week.
Search Interest
Only 5 people have searched for ERAS on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.
MarketBeat Follows
2 people have added Erasca to their MarketBeat watchlist in the last 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Erasca insiders have not sold or bought any company stock.
Percentage Held by Insiders
29.80% of the stock of Erasca is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
49.20% of the stock of Erasca is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Erasca are expected to decrease in the coming year, from ($1.03) to ($1.26) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Erasca is -1.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Erasca is -1.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Erasca has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Erasca (NASDAQ:ERAS) Stock

Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.

ERAS Price History

30 days | 90 days | 365 days | Advanced Chart

ERAS Stock News Headlines

September 19, 2023 | finance.yahoo.com

Erasca to Present at the Cantor Global Healthcare Conference

September 9, 2023 | finance.yahoo.com

Erasca, Inc. (ERAS)

September 28, 2023 | Behind the Markets (Ad)

"Chilling War Games Show US Forces Crushed" – FOX NEWS

=== BREAKING === "Chilling War Games Show US Forces Crushed" - FOX NEWS After losing to China in repeated war games, U.S. military to spend billions on new "living missile" for armed forces. Investors stand to reap 35,960% on shares of small defense contractor that makes powerful new weapon. Get the name of the stock here >>>

September 5, 2023 | finance.yahoo.com

Erasca to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

August 30, 2023 | msn.com

Erasca doses first patient in solid tumours combo therapy trial

August 29, 2023 | finance.yahoo.com

Erasca Doses First Patient in SEACRAFT-1 Phase 1b Trial Evaluating Naporafenib Plus Trametinib in Patients with RAS Q61X Solid Tumors

August 11, 2023 | finanznachrichten.de

Erasca, Inc.: Erasca Reports Second Quarter 2023 Financial Results and Business Updates

August 11, 2023 | markets.businessinsider.com

Erasca (ERAS) Receives a Buy from Mizuho Securities

September 28, 2023 | Behind the Markets (Ad)

"Chilling War Games Show US Forces Crushed" – FOX NEWS

August 11, 2023 | finance.yahoo.com

Erasca Reports Second Quarter 2023 Financial Results and Business Updates

July 12, 2023 | msn.com

Erasca: Trading Near Cash Value

July 6, 2023 | msn.com

Erasca (ERAS) Price Target Decreased by 30.95% to 9.86

June 26, 2023 | benzinga.com

Board Member at Erasca Acquires Company Stock Options Worth 60,000 Shares

June 26, 2023 | benzinga.com

Erasca Board Member Awarded $163K Worth of Stock Options

June 22, 2023 | marketwatch.com

Erasca's Eras-801 for Treatment of Brain Tumors Gets FDA Orphan Drug Designation

June 22, 2023 | markets.businessinsider.com

Erasca's ERAS-801 Gets FDA's Orphan Drug Status

June 22, 2023 | msn.com

FDA grants orphan drug status to Erasca brain cancer drug ERAS-801

June 15, 2023 | finance.yahoo.com

Jonathan Lim Spends US$275k On Erasca Stock

June 15, 2023 | finance.yahoo.com

Jonathan Lim Spends US$275k On Erasca Stock \

June 9, 2023 | benzinga.com

Erasca shares are trading higher after a Form4 filing showed CEO Jonathan Lim acquired 100,000 shares at an average price of $2.75.

June 9, 2023 | benzinga.com

Erasca Insider Trades Send a Signal

June 6, 2023 | msn.com

Mizuho Maintains Erasca (ERAS) Buy Recommendation

June 6, 2023 | markets.businessinsider.com

Analyst Expectations for Erasca's Future

June 6, 2023 | finance.yahoo.com

Erasca Puts Certain Pipeline Programs On Chopping Block To Focus On Programs With Encouraging Activity Signals

June 6, 2023 | markets.businessinsider.com

Erasca (ERAS) Gets a Buy from Goldman Sachs

June 6, 2023 | finanznachrichten.de

Erasca, Inc.: Erasca Provides Update on Clinical Program for ERK Inhibitor ERAS-007 and Refines Pipeline

June 5, 2023 | finance.yahoo.com

Erasca Provides Update on Clinical Program for ERK Inhibitor ERAS-007 and Refines Pipeline

See More Headlines

Receive ERAS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Erasca and its competitors with MarketBeat's FREE daily newsletter.

ERAS Company Calendar

Last Earnings: 8/10/2023
Today: 9/28/2023
Next Earnings (Estimated): 11/08/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ERAS
CUSIP: N/A
CIK: 1761918
Web: www.erasca.com
Phone: 858-465-6511
Fax: N/A
Employees: 129
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $11.00
High Stock Price Forecast: $15.00
Low Stock Price Forecast: $8.00
Forecasted Upside/Downside: +444.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.78)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-242,800,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -35.57%
Return on Assets: -29.04%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 13.90
Quick Ratio: 13.90

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.37 per share
Price / Book: 0.60

Miscellaneous

Outstanding Shares: 151,040,000
Free Float: 106,032,000
Market Cap: $305.10 million
Optionable: Not Optionable
Beta: 1.10

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Dr. Jonathan E. Lim M.D. (Age 51)
Co-Founder, Chairman & CEO
Comp: $940.32k

Dr. David M. Chacko M.D. (Age 39)
CFO & Chief Bus. Officer
Comp: $616.76k

Dr. Michael D. Varney Ph.D. (Age 65)
Chairman of R&D, Scientific Advisory Board Member and Director
Comp: $83.26k

Dr. Nik Chetwyn Ph.D.
Chief Operating Officer

Mr. Ebun S. Garner J.D. (Age 51)
Esq., Gen. Counsel & Corp. Sec.

Dr. Lisa Tesvich-Bonora Ph.D.
Chief People Officer

Mr. Brian L. Baker CPA (Age 56)
M.S., MS, CPA, Sr. VP of Fin.

Ms. Chandra D. Lovejoy M.S. (Age 52)
Chief Regulatory Affairs Officer

Dr. Robert Shoemaker Ph.D. (Age 42)
Sr. VP of Research

Dr. Shannon R. Morris M.D. (Age 53)
Ph.D., Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ERAS Stock - Frequently Asked Questions

Should I buy or sell Erasca stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Erasca in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ERAS shares.
View ERAS analyst ratings or view top-rated stocks.
What is Erasca's stock price forecast for 2023?: 3 Wall Street analysts have issued 1-year price objectives for Erasca's stock. Their ERAS share price forecasts range from $8.00 to $15.00. On average, they expect the company's share price to reach $11.00 in the next year. This suggests a possible upside of 444.6% from the stock's current price.
View analysts price targets for ERAS or view top-rated stocks among Wall Street analysts.
How have ERAS shares performed in 2023?: Erasca's stock was trading at $4.31 at the beginning of the year. Since then, ERAS shares have decreased by 53.1% and is now trading at $2.02.
View the best growth stocks for 2023 here.
Are investors shorting Erasca?: Erasca saw a decline in short interest during the month of September. As of September 15th, there was short interest totaling 8,430,000 shares, a decline of 5.5% from the August 31st total of 8,920,000 shares. Based on an average daily trading volume, of 508,500 shares, the days-to-cover ratio is presently 16.6 days. Currently, 9.1% of the shares of the stock are short sold.
View Erasca's Short Interest.
When is Erasca's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our ERAS earnings forecast.
How were Erasca's earnings last quarter?: Erasca, Inc. (NASDAQ:ERAS) announced its quarterly earnings data on Thursday, August, 10th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.06.
What ETF holds Erasca's stock ?: Virtus LifeSci Biotech Clinical Trials ETF holds 40,125 shares of ERAS stock, representing 0.90% of its portfolio.

When did Erasca IPO?: (ERAS) raised $262 million in an initial public offering on Thursday, July 15th 2021. The company issued 17,500,000 shares at $14.00-$16.00 per share.
What is Erasca's stock symbol?: Erasca trades on the NASDAQ under the ticker symbol "ERAS."
Who are Erasca's major shareholders?: Erasca's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (4.59%), Geode Capital Management LLC (1.07%), Prosight Management LP (1.03%), State Street Corp (0.99%), Nuveen Asset Management LLC (0.78%) and Nuveen Asset Management LLC (0.78%). Insiders that own company stock include Alexander W Casdin, Bihua Chen, Jonathan E Lim and Valerie Denise Harding Start.
View institutional ownership trends.
How do I buy shares of Erasca?: Shares of ERAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Erasca's stock price today?: One share of ERAS stock can currently be purchased for approximately $2.02.
How much money does Erasca make?: Erasca (NASDAQ:ERAS) has a market capitalization of $305.10 million. The company earns $-242,800,000.00 in net income (profit) each year or ($1.78) on an earnings per share basis.
How many employees does Erasca have?: The company employs 129 workers across the globe.
How can I contact Erasca?: The official website for the company is www.erasca.com. The company can be reached via phone at 858-465-6511 or via email at ir@erasca.com.

This page (NASDAQ:ERAS) was last updated on 9/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial